Briefs	E-mail PagePrint Version

NEW STUDY ANALYZES BIOTECH SECTOR

PALO ALTO - A lack of competitive marketing skills and experience in conducting clinical trials is a major drawback of research-based start-up biotech companies, according to a recent analytical report released by industry consultant Frost & Sullivan.
 
Strategic partnering by small biotech companies with larger participants to aid commercialization of its proprietary biotech products can help overcome the problem.

The report  - the US Biotechnology Pipeline Analysis - states that revenue from products in the pipeline totaled $0.21 billion in 2003 and is projected to reach $13.79 billion by 2009.
 
Tactical mergers and joint ventures will help established companies enhance their product portfolios and leverage technology breakthroughs, while smaller companies can benefit from the established company's experience in meeting FDA approval and organized sales policies to successfully handle product commercialization, the report said.
 
To formulate new techniques, the report said, alternate forms of manufacturing such as plant-based pharmaceutical production can be devised or transgenic animals can be evaluated, while a robust pipeline of biologics and the success of approved drugs aid the biotech industry grow dynamically, some technologies such as gene therapy and cellular therapy face negative public perceptions.
 
"Well-managed public relation programs can allay people's misgivings. The FDA also needs to be provided with concrete evidence sustaining the safety of the treatment to help overcome this hurdle," it concluded.

The annual US Biotechnology Pipeline Analysis evaluates the present state of the US biotechnology product pipeline market, determines the market size, estimates revenue forecasts, identifies new opportunities, and maps the changing competitive landscape.
 
The key drivers and restraints are analyzed for each of the leading technology segments: monoclonal antibodies, gene therapy, cancer vaccines, cell therapy, and cytokines.

Go back, or read the latest briefs:

TRADE

empty